ConductScience.org, home

Trial · NCT03110770

Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherMalaiseGeneral disordersPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections1030
otherMalaiseGeneral disordersPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections1030
otherMalaiseGeneral disordersPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections1330
otherMalaiseGeneral disordersPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections4051,162
otherMalaiseGeneral disordersPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections3761,161
otherGastroenteritisInfections and infestationsPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections230
otherGastroenteritisInfections and infestationsPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
otherGastroenteritisInfections and infestationsPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections130
otherGastroenteritisInfections and infestationsPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections111,162
otherGastroenteritisInfections and infestationsPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections171,161
otherPharyngitisInfections and infestationsPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections230
otherPharyngitisInfections and infestationsPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
otherPharyngitisInfections and infestationsPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections030
otherPharyngitisInfections and infestationsPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections281,162
otherPharyngitisInfections and infestationsPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections221,161
otherSinusitisInfections and infestationsPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections030
otherSinusitisInfections and infestationsPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
otherSinusitisInfections and infestationsPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections230
otherSinusitisInfections and infestationsPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections31,162
otherSinusitisInfections and infestationsPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections51,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=4